Three leading generic drugmakers, Sandoz (SDZNY), Teva Pharmaceuticals (TEVA), and Viatris (VTRS), are well-positioned to navigate the evolving landscape of the generic drugs industry. The medical generic drugs sector, which comprises a small 12-stock group, is currently ranked #174 by Zacks, placing it in the bottom 29% of all industries. While the generic drugs market has seen a substantial surge of about 44% over the past year, the industry faces increased competition and persistent price pressures.
Sandoz, now an independent entity spun off from Novartis in 2023, reported Q1 2026 net sales of $2.76 billion, a 3% year-over-year increase, primarily driven by an 18% growth in biosimilars. Teva, the largest global generic drug manufacturer, expects its biosimilars pipeline to generate revenues of $800 million by 2027, while the company achieved significant growth through its branded medications and complex generics. Viatris showcased strong performance in North America thanks to increased demand for its generics and is looking to launch a generic version of Abilify Maintena later this year.
Despite challenges, the strategic investment in differentiated products such as biosimilars and complex generics is essential for future growth. The industry’s forward price-to-earnings ratio currently stands at 15, significantly lower than the S&P 500’s 21.99 and the Zacks Medical sector’s 19.49, indicating a focus on optimizing portfolios and investing in high-margin products to achieve sustainable growth.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
